top of page
August 15, 2022:
We signed a joint development agreement with RaQualia Pharma Inc. for the treatment of intractable and rare diseases that target ion channels.
August 15, 2022:
On April 28, 2022, we raised funds through the issuance of the first J-KISS type stock acquisition rights, with RaQualia Pharma Inc. as the underwriter.
bottom of page